Parkinson's disease and early psychosis Nervous System Diseases
Conditions
Interventions
Participants will complete a computer-based decision-making task, as well as questionnaires probing mood, motivation and cognition. Participants with Parkinson's disease will perform two sessions, onc
Sponsors
University of Birmingham
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Inclusion criteria for those with early psychosis: 1. Aged 18-40 years (inclusive) at the time of eligibility assessment 2. Able to understand written and spoken English 3. Meets one or more criteria for Ultra High Risk for psychosis groups as assessed by the Comprehensive Assessment of At Risk Mental States (CAARMS) or the Structured Interview for Psychosis –Risk Syndromes (SIPS), the Social and Occupational Functioning Assessment Scale (SOFAS) and the Functional Intraoral Glasgow Scale (FIGS) 4. Meets criteria for early/first episode psychosis (meet International Classification of Diseases [ICD-10] criteria for a diagnosis of schizophrenia and related psychoses (ICD-10 code F20, F22, F25, F28, F29) and within 3 years of first diagnosis of psychotic disorder at the time of eligibility assessment Inclusion criteria for those with Parkinson's disease: 1. Age 18-80 years (inclusive) 2. Formal diagnosis of idiopathic Parkinson's disease 3. Able to understand written and spoken English 4. Hoehn and Yahr Parkinson's grade 1 – 4
Exclusion criteria
Exclusion criteria: 1. Lack of capacity/inability to consent 2. Significant neurological or psychiatric comorbidity other than psychosis/at-risk mental state (e.g. significant mood disorder, nervous system disorders such as stroke, traumatic brain injury) 3. Current or lifetime diagnosis of antisocial personality disorder, autism or other neurodevelopmental disorder 4. Significant risk to self or other people, as determined by their clinical team 5. Detained under the Mental Health Act 6. History of alcohol or substance use disorder (abuse/dependence) within 6 months prior to eligibility assessment (nicotine and caffeine dependence are not exclusionary) 7. Significant upper limb motor impairment (i.e. that would impair squeezing a handheld force-meter or clicking a mouse/button) 8. Significant wrist injuries, carpal tunnel syndrome, or musculoskeletal problems that would cause discomfort in squeezing tasks 9. Bed-bound or unable to attend University for in-person study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Reaction time (relating to stimulus presentation to choice interval) measured on each trial; total trials = 320 per experimental session. 2. Choice (relating to which of available options was chosen, corresponding to a level of effort or reward) - measured on each trial; total trials = 320 per experimental session. 3. Self-rated apathy measured using The Dimensional Apathy Scale - total score and dimensional subscores (auto-activation, affective and executive dimensions). Administered once during the first experimental session. 4. (Qualitative study only): Lived experience of apathy symptoms gleaned from clinical interviews in a subset of participants after completing the behavioural task. Leading questions are based on the Lille Apathy Rating Scale (LARS). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Global cognition measured using the Montreal Cognitive Assessment (MOCA) during the first experimental session 2. Mood measured using Patient Health Questionnaire-8 (PHQ-8) during the first experimental session 3. Anhedonia measured using the Snaith-Hamilton Pleasure Scale (SHAPS) during the first experimental session 4. Apathy measured using the Apathy Motivation Index (AMI) during the first experimental session 5. Volume of spontaneous thought, measured using Adapted Glasgow Content of Thoughts Inventory (GCTI) during the first experimental session 6. Fatigue measured using the Fatigue Severity Scale (FSS) during the first experimental session 7. Working memory measured using the digit span test during the first experimental session 8. (Patients with Parkinson's disease): Parkinson's symptom severity measured using the Unified Parkinson's Disease Rating Scale (UPDRS) during the first experimental session. UPDRS part III (motor exam) will also be performed during the second session 9. (Patients with psychosis): Negative symptom burden measured using Brief Negative Symptom Scale (BNSS) during the first session 10. Subjective ratings of choice difficulty (sliding scale between 0-10) recorded during the behavioural task (84 ratings per session) 11. Physical force production (area under curve, maximum force, yank force) recorded during the behavioural task (recorded on every trial of effort subtask; total 160 trials per experimental session) | — |
Countries
England, United Kingdom
Contacts
Public ContactJamie Talbot
Outcome results
None listed